GOSSAMER BIO, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-170.4M | $-56.5M | $-179.8M | $-229.4M | $-234.0M | $-243.4M | $-180.3M | $-147.0M |
| Depreciation & Amortization | $24.0K | $833.0K | $1.6M | $1.8M | $1.7M | $1.4M | $917.0K | $297.0K |
| Depreciation | $0 | $800.0K | $1.6M | $1.8M | $1.7M | $1.4M | $900.0K | $300.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $10.6M | $20.6M | $28.5M | $42.6M | $32.0M | $38.7M | $20.8M | $30.9M |
| Net Cash from Operating Activities | $-171.3M | $-3.5M | $-159.2M | $-187.0M | $-188.9M | $-176.4M | $-144.8M | $-51.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $79.0K | $0 | $0 | $410.0K | $1.5M | $1.5M | $3.0M | $3.5M |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $156.4M | $29.0M | $-111.0M | $-1.0M | $-117.4M | $215.3M | $-147.1M | $-144.7M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $6.4M | $-11.5M | $190.2M | $117.1M | $3.3M | $312.5M | $321.6M | $300.9M |
| Net Change in Cash | $-8.3M | $14.0M | $-79.9M | $-71.5M | $-303.2M | $351.5M | $29.7M | $105.1M |
| Free Cash Flow | $-171.3M | $-3.5M | $-159.2M | $-187.4M | $-190.4M | $-177.9M | $-147.8M | $-54.5M |